NCT03818685View on ClinicalTrials.gov

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

March 15, 2024

Study Completion Date

May 1, 2024

Conditions
Breast CancerTriple Negative Breast Neoplasms
Interventions
DRUG

Nivolumab

Radiotherapy will be maintained in each Arm.

DRUG

Ipilimumab

Radiotherapy will be maintained in each Arm.

DRUG

Capecitabine

Radiotherapy will be maintained in each Arm.

Trial Locations (17)

13273

Institut Paoli Calmettes, Marseille

26000

Hôpital Drôme Ardèche, Valence

37170

Centre d'Oncologie Radiothérapie 37, Chambray-lès-Tours

44805

Institut de Cancérologie de l'Ouest, Saint-Herblain

49055

Institut de Cancérologie de l'Ouest, Angers

51056

Institut Jean Godinot, Reims

67065

Centre Paul Strauss, Strasbourg

69008

Hopital Prive Jean Mermoz, Lyon

69373

Centre Léon Bérard, Lyon

75005

Institut Curie, Paris

75013

GH Pitié-Salpêtrière-Charles Foix, Paris

92201

Institut Curie, Saint-Cloud

Unknown

Institut Sainte Catherine, Avignon

CHRU Besançon, Besançon

Centre Francois Baclesse, Caen

Clinique de la Sauvegarde, Lyon

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Centre Leon Berard

OTHER